Vanda Pharmaceuticals (VNDA) Gains from Investment Securities (2010 - 2026)
Vanda Pharmaceuticals' (VNDA) quarterly Gains from Investment Securities came in at -$280000.0 in Q1 2026, down 130.6% year-on-year from $915000.0 in Q1 2025, and down 105.39% quarter-over-quarter from $5.2 million in Q4 2025.
Vanda Pharmaceuticals (VNDA) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has disclosed Gains from Investment Securities across 17 years of filings, most recently posting -$280000.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$280000.0, down 130.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$280000.0 (down 116.36% YoY), and the FY2025 annual result was $915000.0, up 490.32% from the prior year.
- Gains from Investment Securities came in at -$280000.0 for Q1 2026 at Vanda Pharmaceuticals, down from $5.2 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $5.2 million in Q4 2025 to a low of -$5.2 million in Q3 2025.
- The 5-year median for Gains from Investment Securities is -$552000.0 (2022), against an average of -$111066.7.
- Across the five-year window, Gains from Investment Securities soared 3249.68% in 2025 and plunged 130.6% in 2026, its largest moves.
- Vanda Pharmaceuticals' Gains from Investment Securities stood at -$844000.0 in 2022, then jumped by 428.44% to $2.8 million in 2023, then sank by 94.41% to $155000.0 in 2024, then jumped by 3249.68% to $5.2 million in 2025, then slumped by 105.39% to -$280000.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$280000.0 (Q1 2026), $5.2 million (Q4 2025), and -$5.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Vanda Pharmaceuticals | 345.46 Mn | 143.15 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -280,000.00 |
| Mar 31, 2026 | -280,000.00 |
| Dec 31, 2025 | 5.19 Mn |
| Dec 31, 2025 | 5.19 Mn |
| Sep 30, 2025 | -5.19 Mn |
| Sep 30, 2025 | -5.19 Mn |
| Mar 31, 2025 | 915,000.00 |
| Mar 31, 2025 | 915,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Mar 31, 2024 | -641,000.00 |
| Mar 31, 2024 | -641,000.00 |
| Dec 31, 2023 | 2.77 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | -928,000.00 |
| Sep 30, 2023 | -928,000.00 |
| Jun 30, 2023 | -735,000.00 |
| Jun 30, 2023 | -735,000.00 |